Opera Bioscience

Executive Summary

Opera Bioscience, founded in 2021 and headquartered in San Diego, is a biotechnology company focused on providing high-purity, low-cost recombinant proteins and growth factors for research applications. The company leverages a proprietary bacterial secretion platform that simplifies protein expression and purification, enabling efficient production of biologics for stem cell, organoid, and cell culture markets. By targeting the growing demand for affordable research reagents, Opera Bioscience offers a catalog of standard products alongside custom protein expression and manufacturing services. Its technology aims to reduce costs and improve accessibility for academic and industrial researchers, addressing a critical bottleneck in life science research. Despite being a young private company without disclosed funding or revenue, Opera Bioscience occupies a niche in the protein reagents space, competing with established players by emphasizing purity and cost-effectiveness. The company's business model combines catalog sales with custom services, providing recurring revenue potential and scalability. However, limited public information on financials, clinical pipelines, or partnerships makes it difficult to assess near-term growth. The company's success hinges on expanding its customer base, securing manufacturing contracts, and differentiating its platform. While the market opportunity is substantial, Opera Bioscience remains an early-stage venture with high execution risk.

Upcoming Catalysts (preview)

• Q3 2026Launch of new catalog protein products targeting emerging research areas (e.g., immunotherapy)60% success
• TBDStrategic partnership with a major academic institution or biotech for custom protein supply40% success
• Q3 2026Announcement of seed or Series A funding round to scale operations50% success